CDXS (Codexis Bio) Tingkat bathi miturut bathi reged

Codexis, Inc. (CDXS) is a recognized expert in developing protein catalysts for top pharma behemoths amid growing demand for biosynthesis. This GURU.Markets gross margin chart demonstrates cost efficiency, where 81.30 characterizes this valuation parameter. The company achieves cost optimization by utilizing certified contractors to scale enzyme production from its California complex.
Rincian metrik keuangan lan pasar Codexis, Inc. (CDXS)

Gross margin measures the portion of revenue remaining after covering direct production costs, reflecting the efficiency of cost management and the business's pricing power. For Codexis, Inc. (CDXS), which partners with pharmaceutical behemoths in the biocatalysts segment, the gross profit margin trend confirms the company's ability to monetize its technological superiority in drug synthesis, serving as a key indicator of the model's fundamental stability.